Search

Your search keyword '"Simon Teal"' showing total 4 results
Start Over Author "Simon Teal" Search Limiters Peer Reviewed
4 results on '"Simon Teal"'

1. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial

Author

Carmine Dario Vizza, Pavel Jansa, Simon Teal, Theresa Dombi, and Duo Zhou

Subjects
Sildenafil - Bosentan - pulmonary hypertension - randomized controlled trial -exercise test, Combination therapy, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Background Few controlled clinical trials exist to support oral combination therapy in pulmonary arterial hypertension (PAH). Methods Patients with PAH (idiopathic [IPAH] or associated with connective tissue disease [APAH-CTD]) taking bosentan (62.5 or 125 mg twice daily at a stable dose for ≥3 months) were randomized (1:1) to sildenafil (20 mg, 3 times daily; n = 50) or placebo (n = 53). The primary endpoint was change from baseline in 6-min walk distance (6MWD) at week 12, assessed using analysis of covariance. Patients could continue in a 52-week extension study. An analysis of covariance main-effects model was used, which included categorical terms for treatment, baseline 6MWD (

Published
2017
Full Text
View/download PDF

2. Validation of a claims-based algorithm to identify patients with chronic thromboembolic pulmonary hypertension using electronic health record data

Author

Simon Teal, William R. Auger, Rodney J. Hughes, Dena Rosen Ramey, Kelly S. Lewis, Gerald O'Brien, Avin Yaldo, Tanya M. Burton, Tim Bancroft, Jerry Seare, and Joerg Fabian

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701, Diseases of the respiratory system, RC705-779
Abstract

This study aimed to validate an algorithm developed to identify chronic thromboembolic pulmonary hypertension (CTEPH) among patients with a history of pulmonary embolism. Validation was halted because too few patients had gold-standard evidence of CTEPH in the administrative claims/electronic health records database, suggesting that CTEPH is underdiagnosed.

Published
2018
Full Text
View/download PDF

3. Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database

Author

Ariel Berger, John Edelsberg, Simon Teal, Marko A. Mychaskiw, and Gerry Oster

Subjects
Computer applications to medicine. Medical informatics, R858-859.7
Abstract

**Background:** Pulmonary arterial hypertension (PAH) is a disease characterized by dyspnea, fatigue, chest pain and syncope. As there is no known cure for PAH, the goal of treatment is to control symptoms and slow disease progression. Sildenafil, a phosphodiesterase-5 inhibitor, has been indicated to improve exercise capacity in PAH in both the United States and the European Union since 2005; since 2009, it also has been indicated in the United States to delay clinical worsening. Patterns of sildenafil use in PAH patients have not been reported. **Objectives:** To describe patterns of treatment with sildenafil among commercially insured patients in the United States with PAH. **Methods:** Using a large U.S. healthcare claims database, we identified all patients with evidence of PAH (International Classification of Disease, 9th Revision, Clinical Modification [ICD-9-CM] diagnosis codes 416.0, 416.8) and receipt of sildenafil between January 1, 2005 and September 30, 2008. The date of each patient’s earliest pharmacy claim for sildenafil was designated as his or her “index date”; patients with

Published
2014

4. Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study

Author

Simon Teal, John Edelsberg, MA Mychaskiw, Ariel Berger, and Gerry Oster

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Sildenafil, Hypertension, Pulmonary, Vasodilator Agents, Pulmonary arterial hypertension, PDE5, Phosphodiesterase type 5, Piperazines, Sildenafil Citrate, Cohort Studies, Insurance Claim Review, chemistry.chemical_compound, Internal medicine, Humans, Medicine, Familial Primary Pulmonary Hypertension, Sulfones, Medical prescription, Intensive care medicine, Retrospective Studies, lcsh:RC705-779, Insurance Claim Reporting, business.industry, Clinical Coding, Retrospective cohort study, lcsh:Diseases of the respiratory system, Health Care Costs, Emergency department, Middle Aged, medicine.disease, Pulmonary hypertension, Health expenditure, United States, Primary pulmonary hypertension, Utilization, chemistry, Healthcare utilization, Purines, Female, Diagnosis code, business, Delivery of Health Care, Research Article, Follow-Up Studies, Cohort study
Abstract

Background Little is known concerning the degree to which initiation of sildenafil for pulmonary arterial hypertension (PAH) impacts patterns of healthcare utilization and costs. Methods Using a large US health insurance claims database, we identified all patients with evidence of PAH (ICD-9-CM diagnosis codes 416.0, 416.8) who received sildenafil between 1/1/2005 and 9/30/2008. Date of the first-noted prescription for sildenafil was designated the “index date,” and claims data were compiled for all study subjects for 6 months prior to their index date (“pretreatment”) and 6 months thereafter (“follow-up”); patients with incomplete data during either of these periods were excluded. Healthcare utilization and costs were then compared between pretreatment and follow-up for all study subjects. Results A total of 567 PAH patients were identified who began therapy with sildenafil and met all other study entry criteria. Mean (SD) age was 52 (10) years; 73% were women. Healthcare utilization was largely unchanged between pretreatment and follow-up, the only exceptions being decreases in the mean number of emergency department visits (from 0.7 to 0.5 per patient; p Conclusions The cost of sildenafil therapy may be partially offset by reductions in other healthcare costs.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results